Kurt Zimmerman

[Kurt Zimmerman @kmzimm70]

ISU#7 Rips the helmet right off the QB.

[Kurt Zimmerman @kmzimm70]

@HeavensFX And #7 WTF

[Kurt Zimmerman @kmzimm70]

@AdamSchefter Great move! SOLID

[Kurt Zimmerman @kmzimm70]

@Bengals @paramountplus Play em!!

[Kurt Zimmerman @kmzimm70]

@ZakhariaYousef @UIowaCancer @IntMedatIowa @uihealthcare @IowaMed @BCAN_Research @UIowa_urology @VigneshPackiam @uiowa Outstanding!

[Kurt Zimmerman @kmzimm70]

@ZakhariaYousef The United States and Iowa is fortunate to have you! Congratulations Dr. Zakharia.

[Kurt Zimmerman @kmzimm70]

@KMSinnett Agree 100%.

[Kurt Zimmerman @kmzimm70]

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma - https://t.co/UELWHIAf9F https://t.co/A7KcjXn3W4

[Kurt Zimmerman @kmzimm70]

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study - Merck https://t.co/GASpRJZmJa

[Kurt Zimmerman @kmzimm70]

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma - https://t.co/UELWHIAf9F https://t.co/MDhIbzNKSa

[Kurt Zimmerman @kmzimm70]

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer. https://t.co/RgVGbzd0yM

[Kurt Zimmerman @kmzimm70]

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10) - https://t.co/UELWHIAf9F https://t.co/XyKMjsAecU

[Kurt Zimmerman @kmzimm70]

Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line Metastatic Esophageal Cancer - https://t.co/UELWHIAf9F https://t.co/KpM3Ggoccu

[Kurt Zimmerman @kmzimm70]

Merck - Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC) https://t.co/fr65ow4qaH

[Kurt Zimmerman @kmzimm70]

Merck - FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma https://t.co/OgI3sGFWYb

[Kurt Zimmerman @kmzimm70]

Merck - FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer https://t.co/sSh7KYyiuU